Fig. 4
From: Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein
Target cell cytotoxicity following GrBmut-TRA treatment. Tumor cell lines deficient in or expressing HER2 were plated overnight and subsequently exposed to various concentrations of rGrB, TRA, T-DM1, or GrBmut-TRA. After 48 h, cell viability was determined by crystal violet staining. Target cell viability (%) was calculated based on cells untreated and exposed to 10 μM camptothecin (i.e., maximum cell death). The table inset summarizes EC50 values (ng/mL) across tumor cell lines and treatment conditions. Abbreviations used: CI, 95% confidence intervals; GrB, granzyme B; rGrB, recombinant GrB; GrBmut-TRA, catalytically active AFP; T-DM1, ado-trastuzumab emtansine; TRA, trastuzumab. Bars ± STDEV. Select results are based on technical replicates of 3 samples per treatment group. Individual data values are provided in supplementary information (Additional file 2)